Meclizine HCl Tablets — Class II drug recall D-0005-2022
Ongoing recall by RISING PHARMACEUTICALS, reported 2021-10-13. Labeling: Incorrect Instructions
| Recall number | D-0005-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | RISING PHARMACEUTICALS, East Brunswick, NJ, United States |
| Recall initiated | 2021-09-02 |
| Classified | 2021-10-07 |
| Reported by FDA | 2021-10-13 |
| Quantity | 1,344 bottles |
| Reason classes | labeling |
| NDC | 16571-0752-01 |
| Lot numbers | CB21024 |
| Expiration dates | 2023-02 |
Product
Meclizine HCl Tablets, 25 mg, packaged in 100-count HDPE bottle, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816, Manufactured by: Aurex laboratories LLC, East Windsor, NJ 08520, NDC 16571-752-01
Reason for recall
Labeling: Incorrect Instructions
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0005-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.